Cargando…
4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling
[Image: see text] Epigallocatechin-3-gallate (EGCG), a major green tea polyphenol, has beneficial effects on human health. This study aimed to elucidate the detailed EGCG sulfation process to better understand its phase II metabolism, a process required to maximize its health benefits. Results show...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284555/ https://www.ncbi.nlm.nih.gov/pubmed/35786898 http://dx.doi.org/10.1021/acs.jafc.2c02150 |
_version_ | 1784747587698425856 |
---|---|
author | Hayashi, Akane Terasaka, Shimpei Nukada, Yuko Kameyama, Akiyo Yamane, Masayuki Shioi, Ryuta Iwashita, Masazumi Hashizume, Kohjiro Morita, Osamu |
author_facet | Hayashi, Akane Terasaka, Shimpei Nukada, Yuko Kameyama, Akiyo Yamane, Masayuki Shioi, Ryuta Iwashita, Masazumi Hashizume, Kohjiro Morita, Osamu |
author_sort | Hayashi, Akane |
collection | PubMed |
description | [Image: see text] Epigallocatechin-3-gallate (EGCG), a major green tea polyphenol, has beneficial effects on human health. This study aimed to elucidate the detailed EGCG sulfation process to better understand its phase II metabolism, a process required to maximize its health benefits. Results show that kinetic activity of sulfation in the human liver and intestinal cytosol is 2-fold and 60- to 300-fold higher than that of methylation and glucuronidation, respectively, suggesting sulfation as the key metabolic pathway. Moreover, SULT1A1 and SULT1A3 are responsible for sulfation in the liver and intestine, respectively. Additionally, our human ingestion study revealed that the concentration of EGCG-4″-sulfate in human plasma (C(max): 177.9 nmol·L(–1), AUC: 715.2 nmol·h·L(–1)) is equivalent to free EGCG (C(max): 233.5 nmol·L(–1), AUC: 664.1 nmol·h·L(–1)), suggesting that EGCG-4″-sulfate is the key metabolite. These findings indicate that sulfation is a crucial factor for improving EGCG bioavailability, while also advancing the understanding of the bioactivity and toxicity of EGCG. |
format | Online Article Text |
id | pubmed-9284555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-92845552022-07-16 4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling Hayashi, Akane Terasaka, Shimpei Nukada, Yuko Kameyama, Akiyo Yamane, Masayuki Shioi, Ryuta Iwashita, Masazumi Hashizume, Kohjiro Morita, Osamu J Agric Food Chem [Image: see text] Epigallocatechin-3-gallate (EGCG), a major green tea polyphenol, has beneficial effects on human health. This study aimed to elucidate the detailed EGCG sulfation process to better understand its phase II metabolism, a process required to maximize its health benefits. Results show that kinetic activity of sulfation in the human liver and intestinal cytosol is 2-fold and 60- to 300-fold higher than that of methylation and glucuronidation, respectively, suggesting sulfation as the key metabolic pathway. Moreover, SULT1A1 and SULT1A3 are responsible for sulfation in the liver and intestine, respectively. Additionally, our human ingestion study revealed that the concentration of EGCG-4″-sulfate in human plasma (C(max): 177.9 nmol·L(–1), AUC: 715.2 nmol·h·L(–1)) is equivalent to free EGCG (C(max): 233.5 nmol·L(–1), AUC: 664.1 nmol·h·L(–1)), suggesting that EGCG-4″-sulfate is the key metabolite. These findings indicate that sulfation is a crucial factor for improving EGCG bioavailability, while also advancing the understanding of the bioactivity and toxicity of EGCG. American Chemical Society 2022-07-05 2022-07-13 /pmc/articles/PMC9284555/ /pubmed/35786898 http://dx.doi.org/10.1021/acs.jafc.2c02150 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Hayashi, Akane Terasaka, Shimpei Nukada, Yuko Kameyama, Akiyo Yamane, Masayuki Shioi, Ryuta Iwashita, Masazumi Hashizume, Kohjiro Morita, Osamu 4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling |
title | 4″-Sulfation Is the Major Metabolic Pathway
of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites,
Enzymatic Analysis, and Pharmacokinetic Profiling |
title_full | 4″-Sulfation Is the Major Metabolic Pathway
of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites,
Enzymatic Analysis, and Pharmacokinetic Profiling |
title_fullStr | 4″-Sulfation Is the Major Metabolic Pathway
of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites,
Enzymatic Analysis, and Pharmacokinetic Profiling |
title_full_unstemmed | 4″-Sulfation Is the Major Metabolic Pathway
of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites,
Enzymatic Analysis, and Pharmacokinetic Profiling |
title_short | 4″-Sulfation Is the Major Metabolic Pathway
of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites,
Enzymatic Analysis, and Pharmacokinetic Profiling |
title_sort | 4″-sulfation is the major metabolic pathway
of epigallocatechin-3-gallate in humans: characterization of metabolites,
enzymatic analysis, and pharmacokinetic profiling |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284555/ https://www.ncbi.nlm.nih.gov/pubmed/35786898 http://dx.doi.org/10.1021/acs.jafc.2c02150 |
work_keys_str_mv | AT hayashiakane 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT terasakashimpei 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT nukadayuko 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT kameyamaakiyo 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT yamanemasayuki 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT shioiryuta 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT iwashitamasazumi 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT hashizumekohjiro 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling AT moritaosamu 4sulfationisthemajormetabolicpathwayofepigallocatechin3gallateinhumanscharacterizationofmetabolitesenzymaticanalysisandpharmacokineticprofiling |